§
Luxuse
Patent Intelligence
Sign In
Patent US4386087A successfully refreshed from Google Patents.
← Back to Patent Explorer
US4386087A Expired / Lapsed US ⏱️ 0.0 years remaining

N-Substituted metalloporphyrins as anti-tumor agents against PS-P-388(P388) leukemia in animals

Assignee: Research Foundation of City University of New York
•
Filing: 1981-07-01
•
Granted: 1983-05-31
•
Expires: 2001-07-01
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Alkylating agents have been found to have chemotherapeutic value in cancer treatment. The difficulty of altering the alkylation rate or specificity of alkylating agents is solved by methyl release from metallo N-methyl porphyrins in which the release rate is determined by the particular metal ion of the complex. Moreover, it has been shown that porphyrins accumulate specifically in tumors. Sodium aquo-N-methyltetra (p-sulfophenyl) porphinatocopper (II) trifluoromethanesulfonate has been shown to have activity against lymphocytic PS-P-388 (P388) leukemia in mammals. A wide range of N-substituents and metallo complexes, and their preparation are given. Anti-tumor use is demonstrated against P388 leukemia in animals.

Inventors

  • 👤 David K. Lavallee

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-28 23:34
CPC Classifications
C; C07; C07D; C07D487/00; C07D487/22; A; A61; A61K; A61K31/00; A61K31/33; A61K31/555

Claims Analysis

Total Claims: 2
Claim 1
Independent Claim 37 words
The method of treating lymphocytic PS-P-388 leukemia in a mammal comprising the injection by injection of to said mammal of, sodium aquo-N-methyltetra(p-sulfophenyl)porphinato copper (II) trifluoromethane sulfonate in a daily dose rate of 6-100 mg/kilogram of body weight.
Claim 2
Independent Claim 37 words
The method of treating lymphocytic PS-P-388 leukemia in a mammal comprising the injection by injection of to said mammal of, sodium aquo-N-methyltetra(p-sulfophenyl)porphinato copper (II) trifluoromethane sulfonate in a daily dose rate of 6-100 mg/kilogram of body weight.

References Cited (Backward Citations)

US2858320A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1986-05-30 1986-11-29 1987-05-31 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1990-05-30 1990-11-29 1991-05-31 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1994-05-30 1994-11-29 1995-05-31 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag